相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Unraveling the Gordian knot: genetics and the troubled road to effective therapeutics for Alzheimer's disease
Linda L. Restifo
GENETICS (2022)
Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease
Stephen Salloway et al.
JAMA NEUROLOGY (2022)
Novel strategies for the fight of Alzheimer's disease targeting amyloid-β protein
Yang Xie et al.
JOURNAL OF DRUG TARGETING (2022)
The Ups and Downs of Amyloid in Alzheimer's
E. Siemers et al.
JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE (2022)
The Development of Pharmacological Therapies for Alzheimer's Disease
Ping Lin et al.
NEUROLOGY AND THERAPY (2021)
Critical thinking on amyloid-beta-targeted therapy: challenges and perspectives
Bin-lu Sun et al.
SCIENCE CHINA-LIFE SCIENCES (2021)
Past, present and future of therapeutic strategies against amyloid-β peptides in Alzheimer's disease: a systematic review
Danko Jeremic et al.
AGEING RESEARCH REVIEWS (2021)
Therapeutic Strategies Targeting Amyloid-beta Receptors and Transporters in Alzheimer's Disease
Kejing Lao et al.
JOURNAL OF ALZHEIMERS DISEASE (2021)
The Alzheimer's disease drug development landscape
Pieter van Bokhoven et al.
ALZHEIMERS RESEARCH & THERAPY (2021)
Evaluation of Aducanumab for Alzheimer Disease Scientific Evidence and Regulatory Review Involving Efficacy, Safety, and Futility
G. Caleb Alexander et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody
Chad J. Swanson et al.
ALZHEIMERS RESEARCH & THERAPY (2021)
Aducanumab produced a clinically meaningful benefit in association with amyloid lowering
Jeffrey Cummings et al.
ALZHEIMERS RESEARCH & THERAPY (2021)
Effects of monoclonal antibodies against amyloid-β on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer's disease
Konstantinos Avgerinos et al.
AGEING RESEARCH REVIEWS (2021)
Critical Appraisal of Amyloid Lowering Agents in AD
Boris Decourt et al.
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS (2021)
Alzheimer's and Aducanumab: Unjust Profits and False Hopes
Leonard M. Fleck
HASTINGS CENTER REPORT (2021)
Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer's Pathogenesis and Represent a Clinically Validated Target for Slowing Disease Progression
Martin Tolar et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Novel Therapeutic Approaches for Alzheimer's Disease: An Updated Review
Tien-Wei Yu et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Approval of Aducanumab for Alzheimer Disease-the FDA's Perspective
Billy Dunn et al.
JAMA INTERNAL MEDICINE (2021)
Donanemab (LY3002813) Phase 1b Study in Alzheimer's Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging
S. L. Lowe et al.
JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE (2021)
Aducanumab: Appropriate Use Recommendations
J. Cummings et al.
JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE (2021)
2021 Alzheimer's disease facts and figures
[Anonymous]
ALZHEIMERS & DEMENTIA (2021)
Thirty-Six-Month Amyloid Positron Emission Tomography Results Show Continued Reduction in Amyloid Burden with Subcutaneous Gantenerumab
Gregory Klein et al.
JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE (2021)
Lanabecestat: Neuroimaging results in early symptomatic Alzheimer's disease
Jennifer A. Zimmer et al.
ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS (2021)
The path forward in Alzheimer's disease therapeutics: Reevaluating the amyloid cascade hypothesis
Martin Tolar et al.
ALZHEIMERS & DEMENTIA (2020)
WHO's global action plan on the public health response to dementia: some challenges and opportunities
Suzanne Cahill
AGING & MENTAL HEALTH (2020)
APP Osaka Mutation in Familial Alzheimer's Disease-Its Discovery, Phenotypes, and Mechanism of Recessive Inheritance
Takami Tomiyama et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
A mechanistic hypothesis for the impairment of synaptic plasticity by soluble Aβ oligomers from Alzheimer's brain
Shaomin Li et al.
JOURNAL OF NEUROCHEMISTRY (2020)
What works and what does not work in Alzheimer's disease? From interventions on risk factors to anti-amyloid trials
Szofia Bullain et al.
JOURNAL OF NEUROCHEMISTRY (2020)
Cognitive outcomes in trials of two BACE inhibitors in Alzheimer's disease
Alette M. Wessels et al.
ALZHEIMERS & DEMENTIA (2020)
Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer's disease
Tiantian Guo et al.
MOLECULAR NEURODEGENERATION (2020)
Behavioral and neural network abnormalities in human APP transgenic mice resemble those ofAppknock-in mice and are modulated by familial Alzheimer's disease mutations but not by inhibition of BACE1
Erik C. B. Johnson et al.
MOLECULAR NEURODEGENERATION (2020)
Amyloid Hypothesis: The Emperor's New Clothes?
Poul F. Hoilund-Carlsen et al.
JOURNAL OF ALZHEIMERS DISEASE (2020)
Systematic and standardized comparison of reported amyloid- receptors for sufficiency, affinity, and Alzheimer's disease relevance
Levi M. Smith et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2019)
Amyloid Beta Oligomers Target to Extracellular and Intracellular Neuronal Synaptic Proteins in Alzheimer's Disease
Yu Ding et al.
FRONTIERS IN NEUROLOGY (2019)
Are antibodies directed against amyloid- (A) oligomers the last call for the A hypothesis of Alzheimer's disease?
Francesco Panza et al.
IMMUNOTHERAPY (2019)
Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer's disease: a PET substudy interim analysis
Gregory Klein et al.
ALZHEIMERS RESEARCH & THERAPY (2019)
Amyloid β oligomers (AβOs) in Alzheimer's disease
Barbara Mroczko et al.
JOURNAL OF NEURAL TRANSMISSION (2018)
Diffusible, highly bioactive oligomers represent a critical minority of soluble A beta in Alzheimer's disease brain
Wei Hong et al.
ACTA NEUROPATHOLOGICA (2018)
The Amyloid-beta Oligomer Hypothesis: Beginning of the Third Decade
Erika N. Cline et al.
JOURNAL OF ALZHEIMERS DISEASE (2018)
The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non-human primate model of Alzheimer's disease
Andre F. Batista et al.
JOURNAL OF PATHOLOGY (2018)
An integrated strategy to correlate aggregation state, structure and toxicity of A beta 1-42 oligomers
Federica Bisceglia et al.
TALANTA (2018)
An acute functional screen identifies an effective antibody targeting amyloid-β oligomers based on calcium imaging
Xueying Wang et al.
SCIENTIFIC REPORTS (2018)
Alzheimer's disease (AD) therapeutics-1: Repeated clinical failures continue to question the amyloid hypothesis of AD and the current understanding of AD causality
Kevin Mullane et al.
BIOCHEMICAL PHARMACOLOGY (2018)
THE AMYLOID HYPOTHESIS ON TRAIL
Simon Makin
NATURE (2018)
Efficacy of chronic BACE1 inhibition in PS2APP mice depends on the regional Aβ deposition rate and plaque burden at treatment initiation
Matthias Brendel et al.
THERANOSTICS (2018)
Questions concerning the role of amyloid-beta in the definition, aetiology and diagnosis of Alzheimer's disease
Gary P. Morris et al.
ACTA NEUROPATHOLOGICA (2018)
Human Brain-Derived Aβ Oligomers Bind to Synapses and Disrupt Synaptic Activity in a Manner That Requires APP
Zemin Wang et al.
JOURNAL OF NEUROSCIENCE (2017)
Evaluation of Small-Animal PET Outcome Measures to Detect Disease Modification Induced by BACE Inhibition in a Transgenic Mouse Model of Alzheimer Disease
Steven Deleye et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
Amyloid in Alzheimer's Disease: Guilty Beyond Reasonable Doubt?
Christian Behl
TRENDS IN PHARMACOLOGICAL SCIENCES (2017)
A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease
Susanne Ostrowitzki et al.
ALZHEIMERS RESEARCH & THERAPY (2017)
Neurons derived from sporadic Alzheimer's disease iPSCs reveal elevated TAU hyperphosphorylation, increased amyloid levels, and GSK3B activation
Anna Ochalek et al.
ALZHEIMERS RESEARCH & THERAPY (2017)
Non-Fibrillar Oligomeric Amyloid-beta within Synapses
Eleanor K. Pickett et al.
JOURNAL OF ALZHEIMERS DISEASE (2016)
The antibody aducanumab reduces Aβ plaques in Alzheimer's disease
Jeff Sevigny et al.
NATURE (2016)
Safety and tolerability of BAN2401-a clinical study in Alzheimer's disease with a protofibril selective Aβ antibody
Veronika Logovinsky et al.
ALZHEIMERS RESEARCH & THERAPY (2016)
The Binding Receptors of Aβ: an Alternative Therapeutic Target for Alzheimer's Disease
Min Xia et al.
MOLECULAR NEUROBIOLOGY (2016)
Amyloid β oligomers in Alzheimer's disease pathogenesis, treatment, and diagnosis
Kirsten L. Viola et al.
ACTA NEUROPATHOLOGICA (2015)
Soluble amyloid-β oligomers as synaptotoxins leading to cognitive impairment in Alzheimer's disease
Sergio T. Ferreira et al.
FRONTIERS IN CELLULAR NEUROSCIENCE (2015)
Genetic Modulation of Soluble Aβ Rescues Cognitive and Synaptic Impairment in a Mouse Model of Alzheimer's Disease
Stephanie W. Fowler et al.
JOURNAL OF NEUROSCIENCE (2014)
Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer's disease immunotherapeutics
William F. Goure et al.
ALZHEIMERS RESEARCH & THERAPY (2014)
Inconsistencies and Controversies Surrounding the Amyloid Hypothesis of Alzheimer's Disease
Gary P. Morris et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2014)
New ELISAs with high specificity for soluble oligomers of amyloid β-protein detect natural Aβ oligomers in human brain but not CSF
Ting Yang et al.
ALZHEIMERS & DEMENTIA (2013)
Alzheimer's therapeutics: Continued clinical failures question the validity of the amyloid hypothesis-but what lies beyond?
Kevin Mullane et al.
BIOCHEMICAL PHARMACOLOGY (2013)
Specific Uptake of an Amyloid-β Protofibril-Binding Antibody-Tracer in AβPP Transgenic Mouse Brain
Kristina Magnusson et al.
JOURNAL OF ALZHEIMERS DISEASE (2013)
Promiscuous Alzheimer's Amyloid: Yet Another Partner
Iryna Benilova et al.
SCIENCE (2013)
The case for soluble Aβ oligomers as a drug target in Alzheimer's disease
Franz Hefti et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2013)
Amyloid beta-protein oligomers and Alzheimer's disease
Eric Y. Hayden et al.
ALZHEIMERS RESEARCH & THERAPY (2013)
Apolipoprotein E4 effects in Alzheimer's disease are mediated by synaptotoxic oligomeric amyloid-β
Robert M. Koffie et al.
BRAIN (2012)
Large Aggregates Are the Major Soluble Ab Species in AD Brain Fractionated with Density Gradient Ultracentrifugation
Dag Sehlin et al.
PLOS ONE (2012)
Alzheimer's disease Aβ assemblies mediating rapid disruption of synaptic plasticity and memory
Igor Klyubin et al.
MOLECULAR BRAIN (2012)
Thy1-hAPPLond/Swe+ mouse model of Alzheimer's disease displays broad behavioral deficits in sensorimotor, cognitive and social function
Mehrdad Faizi et al.
BRAIN AND BEHAVIOR (2012)
Structural dynamics of the ΔE22 (Osaka) familial Alzheimer's disease-linked amyloid β-protein
Mohammed Inayathullah et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2011)
A Longitudinal Study of Behavioral Deficits in an A beta PP Transgenic Mouse Model of Alzheimer's Disease
Daniel Havas et al.
JOURNAL OF ALZHEIMERS DISEASE (2011)
Cognitive effects of cell-derived and synthetically derived Aβ oligomers
Miranda N. Reed et al.
NEUROBIOLOGY OF AGING (2011)
The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease
Sergio T. Ferreira et al.
NEUROBIOLOGY OF LEARNING AND MEMORY (2011)
Therapeutic significance of NR2B-containing NMDA receptors and mGluR5 metabotropic glutamate receptors in mediating the synaptotoxic effects of β-amyloid oligomers on long-term potentiation (LTP) in murine hippocampal slices
Gerhard Rammes et al.
NEUROPHARMACOLOGY (2011)
Aβ Oligomers Cause Localized Ca2+ Elevation, Missorting of Endogenous Tau into Dendrites, Tau Phosphorylation, and Destruction of Microtubules and Spines
Hans Zempel et al.
JOURNAL OF NEUROSCIENCE (2010)
11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study
Juha O. Rinne et al.
LANCET NEUROLOGY (2010)
Structural conversion of neurotoxic amyloid-β1-42 oligomers to fibrils
Mahiuddin Ahmed et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2010)
Anti-ADDL antibodies differentially block oligomer binding to hippocampal neurons
P. J. Shughrue et al.
NEUROBIOLOGY OF AGING (2010)
Alzheimer's Disease Amyloid β-Protein and Synaptic Function
Tomas Ondrejcak et al.
NEUROMOLECULAR MEDICINE (2010)
ADDLs and the signaling web that leads to Alzheimer's disease
Grant A. Krafft et al.
NEUROPHARMACOLOGY (2010)
Alzheimer's disease: synaptic dysfunction and Aβ
Ganesh M. Shankar et al.
MOLECULAR NEURODEGENERATION (2009)
IgG2m4, an engineered antibody isotype with reduced Fc function
Zhiqiang An et al.
MABS (2009)
Cellular prion protein mediates impairment of synaptic plasticity by amyloid-β oligomers
Juha Lauren et al.
NATURE (2009)
Amyloid-β protein oligomerization and the importance of tetramers and dodecamers in the aetiology of Alzheimer's disease
Summer L. Bernstein et al.
NATURE CHEMISTRY (2009)
An amyloid-β protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer's disease
Anna Lord et al.
NEUROBIOLOGY OF DISEASE (2009)
Oligomeric amyloid β associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques
Robert M. Koffie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
A new amyloid μ variant favoring oligomerization in Alzheimer's-type dementia
Takami Tomiyama et al.
ANNALS OF NEUROLOGY (2008)
Oligomers of the amyloid-β protein disrupt working memory:: Confirmation with two behavioral procedures
Alan Poling et al.
BEHAVIOURAL BRAIN RESEARCH (2008)
Alzheimer's disease-type neuronal tau hyperphosphorylation induced by Aβ oligomers
Fernanda G. De Felice et al.
NEUROBIOLOGY OF AGING (2008)
Sensitive ELISA detection of amyloid-β protofibrils in biological samples
Hillevi Englund et al.
JOURNAL OF NEUROCHEMISTRY (2007)
Accelerating amyloid-β fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models
Irene H. Cheng et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
A beta Oligomers - a decade of discovery
Dominic M. Walsh et al.
JOURNAL OF NEUROCHEMISTRY (2007)
Solution state characterization of amyloid β-derived diffusible ligands
Robert W. Hepler et al.
BIOCHEMISTRY (2006)
Effects of secreted oligomers of amyloid β-protein on hippocampal synaptic plasticity:: a potent role for trimers
M Townsend et al.
JOURNAL OF PHYSIOLOGY-LONDON (2006)
A specific amyloid-β protein assembly in the brain impairs memory
S Lesné et al.
NATURE (2006)
Globular amyloid β-peptide1-42 oligomer -: a homogenous and stable neuropathological protein in Alzheimer's disease
S Barghorn et al.
JOURNAL OF NEUROCHEMISTRY (2005)
Natural oligomers of the amyloid-protein specifically disrupt cognitive function
JP Cleary et al.
NATURE NEUROSCIENCE (2005)
Small assemblies of unmodified amyloid β-protein are the proximate neurotoxin in Alzheimer's disease
WL Klein et al.
NEUROBIOLOGY OF AGING (2004)
Oligomers in the brain: The emerging role of soluble protein aggregates in neurodegeneration
DM Walsh et al.
PROTEIN AND PEPTIDE LETTERS (2004)
Mechanisms of the inhibitory effects of amyloid β-protein on synaptic plasticity
MJ Rowan et al.
EXPERIMENTAL GERONTOLOGY (2004)
Self-assembly of Aβ1-42 into globular neurotoxins
BA Chromy et al.
BIOCHEMISTRY (2003)
Alzheimer's disease-affected brain:: Presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss
YS Gong et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Paradigm shifts in Alzheimer's disease and other neuro degenerative disorders: The emerging role of oligomeric assemblies
MD Kirkitadze et al.
JOURNAL OF NEUROSCIENCE RESEARCH (2002)
Amyloid-β oligomers:: their production, toxicity and therapeutic inhibition
DM Walsh et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2002)
Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo
DM Walsh et al.
NATURE (2002)
Vaccination with soluble Aβ oligomers generates toxicity-neutralizing antibodies
MP Lambert et al.
JOURNAL OF NEUROCHEMISTRY (2001)
Targeting small Aβ oligomers:: the solution to an Alzheimer's disease conundrum?
WL Klein et al.
TRENDS IN NEUROSCIENCES (2001)
High-level neuronal expression of Aβ1-42 in wild-type human amyloid protein precursor transgenic mice:: Synaptotoxicity without plaque formation
L Mucke et al.
JOURNAL OF NEUROSCIENCE (2000)
分享论文
